To improve the lives of patients and their families.

To provide medicines that slow, stop, or revert the progression.

By targeting the pathology of toxic misfolded proteins.

Our Programs

Structured for Success

Based in the biotech hub of San Diego, our in-house expertise of our people and global collaborations with academic and industry partners allow us to discover novel therapeutic targets and develop innovative therapeutics.  

About Our Team


Neuropore Therapies Awarded Second Grant on its TLR2 Program from The Michael J. Fox Foundation for Parkinson’s Research January 4, 2018

Neuropore Therapies, Inc. has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

See All News


Neuropore Therapies (NPT™) Presents at the 2018 Advances in Alzheimer's and Parkinson's Therapies - an AAT-AD/PD Focus Meeting in Torino, Italy  March 15th, 2018  The poster presentations entitled, "Beneficial effects of NPT520-34 in multiple models of neurodegenerative disorders", will be presented by Dr. Diana L. Price. 

here for more information.

See All Events

NPTTM Publications

Neuropore publishes paper describing the discovery and characterization of a small molecule compound targeting α-synuclein as a potential Parkinson’s disease therapeutic October 5th, 2016

Report in Brain, describes findings supporting the hypothesis that NPTTM100-18A reduces alpha-synuclein toxicity through a novel mechanism that involves displacing pathological alpha-synuclein from the membrane.

See All Publications


Our Major Partnerships

Ever Neuro Pharma
The Michael J. Fox Foundation for Parkinson's Research
Neuropore Video

Our Technology

Learn about Neuropore’s two part development strategy targeting misfolded proteins -- the key pathological culprit(s) underlying neurodegenerative disorders.

Learn More See All Videos